Biotron (Biotron) Net Income From Continuing Operations : $-2.70 Mil (TTM As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Biotron Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Biotron's net income from continuing operations for the six months ended in Dec. 2023 was $-0.89 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.70 Mil.

Biotron Net Income From Continuing Operations Historical Data

The historical data trend for Biotron's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotron Net Income From Continuing Operations Chart

Biotron Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Net Income From Continuing Operations

Get a 7-Day Free Trial

-1.12

-2.47

-2.44

-1.95

-2.34

Biotron Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Income From Continuing Operations	Get a 7-Day Free Trial															-1.39	-0.59	-0.54	-1.81	-0.89

Biotron Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-2.70 Mil.

Biotron (Biotron) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotron Ltd (OTCPK:BITRF) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

BIT:Australia

Address

56 Delhi Road, Suite 3.3, North Ryde, Sydney, NSW, AUS, 2113

Website

https://www.biotron.com.au

Biotron Ltd is a biotechnology company. It is engaged in the funding and management of intermediate and applied biotechnology research and development projects. Its antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. Geographically, it operates only in Australia through biotechnology segment.

Biotron (Biotron) Headlines

From GuruFocus

Biotron Drug Effective Against COVID-19 In Animals

By PRNewswire PRNewswire • 11-25-2021